<DOC>
	<DOCNO>NCT00567762</DOCNO>
	<brief_summary>To investigate efficacy safety FK506 ophthalmic suspension eye symptom patient vernal keratoconjunctivitis</brief_summary>
	<brief_title>Phase III Study 0.1 % Tacrolimus ( FK506 ) Ophthalmic Suspension Patients With Vernal Keratoconjunctivitis</brief_title>
	<detailed_description>0.1 % FK506 ophthalmic suspension administer twice-a-day patient vernal keratoconjunctivitis treatment topical anti-allergic agent ineffective . The primary efficacy endpoint mean change baseline ( treatment ) total score objective clinical sign final observation . The safety FK506 ophthalmic suspension also investigate .</detailed_description>
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Keratoconjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis , Allergic</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Vernal keratoconjunctivitis patient diagnose `` Guideline diagnosis treatment allergic conjunctival disease '' Patients type I reaction define skin testing , antibody measurement , etc . Age 6 year old Subjects receive systemic administration subconjunctival injection corticosteroid immunosuppressant ( ophthalmic systemic medication ) within 2weeks initiation study Subjects need wear contact lenses treatment period test eye Subjects complicate eye infection</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Keratoconjunctivitis</keyword>
	<keyword>vernal keratoconjunctivitis</keyword>
	<keyword>FK506</keyword>
	<keyword>Tacrolimus</keyword>
</DOC>